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Abstract
Background: Several inflammatory lung diseases display abundant presence of hyaluronic acid (HA) bound to
heavy chains (HC) of serum protein inter-alpha-inhibitor (IαI) in the extracellular matrix. The HC-HA modification is
critical to neutrophil sequestration in liver sinusoids and to survival during experimental lipopolysaccharide (LPS)-
induced sepsis. Therefore, the covalent HC-HA binding, which is exclusively mediated by tumor necrosis factor α
(TNFα)-stimulated-gene-6 (TSG-6), may play an important role in the onset or the resolution of lung inflammation in
acute lung injury (ALI) induced by respiratory infection.
Methods: Reversible ALI was induced by a single intratracheal instillation of LPS or Pseudomonas aeruginosa in
mice and outcomes were studied for up to six days. We measured in the lung or the bronchoalveolar fluid HC-HA
formation, HA immunostaining localization and roughness, HA fragment abundance, and markers of lung
inflammation and lung injury. We also assessed TSG-6 secretion by TNFα- or LPS-stimulated human alveolar
macrophages, lung fibroblast Wi38, and bronchial epithelial BEAS-2B cells.
Results: Extensive HC-modification of lung HA, localized predominantly in the peri-broncho-vascular extracellular
matrix, was notable early during the onset of inflammation and was markedly decreased during its resolution.
Whereas human alveolar macrophages secreted functional TSG-6 following both TNFα and LPS stimulation,
fibroblasts and bronchial epithelial cells responded to only TNFα. Compared to wild type, TSG-6-KO mice, which
lacked HC-modified HA, exhibited modest increases in inflammatory cells in the lung, but no significant differences
in markers of lung inflammation or injury, including histopathological lung injury scores.
Conclusions: Respiratory infection induces rapid HC modification of HA followed by fragmentation and clearance, with
kinetics that parallel the onset and resolution phase of ALI, respectively. Alveolar macrophages may be an important
source of pulmonary TSG-6 required for HA remodeling. The formation of HC-modified HA had a minor role in the onset,
severity, or resolution of experimental reversible ALI induced by respiratory infection with gram-negative bacteria.
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Background
The extracellular matrix actively participates in inflammatory
signaling, tissue remodeling, and repair of various tissues. A
better understanding of how components of the extracellular
matrix participate in acute lung injury (ALI) and repair may
provide new therapeutic targets for clinical conditions such
as acute respiratory distress syndrome. Hyaluronic acid
(HA) is an unsulfated glycosaminoglycan (extracellular
matrix polysaccharide with repeating disaccharide unit) that
can be covalently modified with the heavy chains (HC) of
serum protein inter-alpha-inhibitor (IαI) during inflamma-
tion [1–5], in a reaction exclusively mediated by tumor ne-
crosis factor α (TNFα)-stimulated gene-6 (TSG-6) protein
(Additional file 1). Building on reports that TSG-6 mediated
formation of HC-modified HA is critical to neutrophil se-
questration in liver sinusoids [6, 7] and an important pro-
tective mediator of survival in lipopolysaccharide (LPS)
models of sepsis [6, 8–10], we investigated the role of
HC-HA in ALI induced by respiratory infections, modeled
by LPS or bacteria.
HC-modified HA is prominently featured in the extracel-
lular matrix of chronic lung diseases such as pulmonary ar-
terial hypertension [11], asthma [12], cystic fibrosis [13],
and idiopathic pulmonary fibrosis [14], that share lung in-
flammation in their pathogenesis, suggesting that HC-HA
formation is important in either promoting the onset or
delaying the resolution of lung inflammation. We therefore
used self-resolving models of ALI that were induced by
intratracheal instillation of LPS or gram negative bacteria
Pseudomonas aeruginosa (PA) to study the kinetics and role
of HC-modified HA in acute lung inflammation. In
addition to using TSG-6-knockout (KO) mice to address
the functional role of HC-HA formation in ALI, we de-
scribe that LPS and PA induce extensive HC-HA formation
during the initial phase of injury, followed by fragmentation
and clearance of HC-modified HA.
Materials and reagents
All materials and reagents used were from ThermoFisher
(Waltham, MA, USA) unless otherwise specified. Reagents
from Gibco (ThermoFisher) were used for cell culture.
Mice
All animal experiments in this paper were approved by
the Institutional Animal Care and Use Committee
(IACUC) at National Jewish Health. TSG-6-KO mice
(BALB/c background) were originally generated by Dr.
Katalin Mikecz [15]. Studies were conducted using sex-
and age matched TSG-6-KO mice and wild type (WT)
and heterozygous (HT) littermate controls.
Murine acute lung injury models
Escherichia coli (E. coli) LPS (20 μg LPS in 50 μL phos-
phate buffered saline (PBS), L2880, MilliporeSigma,
Burlington, MA, USA) or gram negative PA bacteria (2 ×
106 CFU, colony forming unit, PA01 strain) was instilled
directly into the tracheas of 10–12 week old mice using a
22-gauge oral gavage needle (7920, Cadence Science,
Cranston, RI, USA) with its distal 0.5 cm end bent 40° to
facilitate tracheal insertion. PA was provided by Dr. Ken-
neth Malcolm (National Jewish Health) and originally ob-
tained from Pseudomonas Genetic Stock Center (East
Carolina University) [15]. PA was grown in Luria-Bertani
broth (LB), and PA in the exponential phase of growth
was centrifuged and resuspended in 50 μL PBS for instilla-
tion. CFU was confirmed by plating dilutions of PA on LB
agar. Mice weight was assessed every 24 h, for up to 6 days
post-instillation.
Methods
Lung HC-HA
HC-HA formation in lung tissue was measured as de-
scribed previously [16] with minor modifications. Briefly,
equal mass (50 mg) of flash frozen mouse lung tissue
was homogenized in PBS for 3 min using
Mini-Beadbeater-16 (Biospec, Bartlesville, OK, USA) and
treated with 1 U of Streptomyces hyaluronidase (389,561,
MilliporeSigma) or PBS control for 45 min at 4 °C with
mechanical agitation. Samples were then centrifuged
(13,000 g, 5 min, 4 °C) and supernatants were then incu-
bated (37 °C; 30 min) with mechanical agitation. The
samples were then combined with Laemmli Buffer, sepa-
rated by SDS-PAGE (Stain-free Criterion TGX 7.5% gels,
Biorad, Hercucles, CA, USA) and transferred to
Immobilon-P PVDF membrane (MilliporeSigma) using
TransBlot Semi-Dry (Biorad). The western blot was
probed using rabbit-anti-hIαI antibody (A0301, DAKO,
Agilent, Santa Clara, CA, USA), which has been vali-
dated for detecting mouse IαI and HC-HA formation in
injured mouse lung [17]. ChemiDoc MP (Biorad) was
used to image the Stain-free gels for total protein. Densi-
tometry was performed using Image Studio Lite (Licor,
Lincoln, NE, USA).
Messenger RNA (mRNA) studies
Total ribonucleic acid (RNA) was extracted from cul-
tured cells using RNeasy Mini Plus (Qiagen, German-
town, MD, USA) and from whole lung using Trizol
Plus RNA Purification Kit with on-column deoxyribo-
nuclease (DNAse) digest performed using PureLink
DNase. Mouse lung was homogenized in Trizol using
Mini-Beadbeater-16 (Biospec); 1000–2000 ng of total
extracted RNA was used to synthesize complementary
DNA (cDNA) (High-Capacity cDNA Reverse Tran-
scription). Real-time quantitative polymerase chain re-
action (qPCR) was performed on the StepOnePlus
System using Taqman Universal PCR Master Mix and
Taqman probes: hTSG-6 (Hs01113602_m1), msTNFα
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(Mm00443258_m1), msTSG-6 (Mm00493736_m1) [18, 19],
msHAS1 (Mm03048195_m1), msHAS2 (Mm00515089_
m1), msHAS3 (Mm00515092_m1), msHYAL1 (Mm004
76206_m1), msHYAL2 (Mm01230688_g1), msTMEM2
(Mm00459599_m1), and msCEMIP (Mm00472921_m1).
Relative mRNA expression was calculated using the double
delta comparative (ΔΔCt) method and 18 s RNA endogen-
ous control (Taqman Hs99999901_s1).
HA histology
Mice were euthanized by isoflurane overdose, bilateral
thoracotomy, and perfusion of the lungs via the right ven-
tricle using 10 mL of blood bank saline. LPS injured lungs
were inflated with a PBS equilibrated solution containing
4% paraformaldehyde (PFA) (15,710, Electron Microscopy
Sciences, Hatfield, PA, USA) and 0.33% low melting point
agarose. Inflated lungs were immersion fixed overnight
(24 h) in 4% PFA at 4 °C with gentle rocking and then se-
quentially incubated for 1 h in PBS and 4 h in PBS con-
taining 25% sucrose and 25% optimal cutting temperature
(OCT) compound. The lungs were then embedded in
OCT compound and frozen using dry ice. Ten μm sec-
tions were cut using a cryostat and allowed to air dry be-
fore washing in PBS to remove OCT compound.
PA injured lungs were inflated with 10% neutral buff-
ered formalin containing 0.25% low melting point agar-
ose and then immersion fixed in 10% neutral buffered
formalin overnight at room temperature before paraffin
embedding and sectioning (3 μm). Paraffin embedded
tissue sections were then mounted on slides and proc-
essed as follows: mounted tissues were deparafinized
and rehydrated using successive incubations in xylene
(3 × 5 min), 100% ethanol (2 × 5 min), 95% ethanol
(2 × 5 min) and equilibration in PBS followed by
water. The tissue was then placed in pressure cooker
containing citric acid based antigen unmasking solu-
tion (Vector Labs, Burlingame, CA, USA) and
microwaved.
Staining of lung sections was performed as follows: tis-
sue sections were blocked using PBS solution containing
3% bovine serum albumin (BSA, MilliporeSigma) and
0.1% Triton X-100 (MilliporeSigma). Biotinylated hyalur-
onan binding protein (50 μg/100 μl stock, 385,911, Milli-
poreSigma), rabbit anti-human HC2 (NBP2–31750,
Novus, Littleton, CO, USA), and rat anti-mouse CD68
(FA-11, Biolegend, San Diego, CA) were added at 1:100
and incubated overnight at 4 °C. Streptavidin Alexa
Flour 488 (S-11223) was used at 1:1000. Cy3 donkey
anti-rabbit (711–165-152, Jackson ImmunoResearch,
West Grove, PA, USA) and Cy5 donkey anti-rat (712–
175-153, Jackson ImmunoResearch) were used at 1:2000.
Tissue was mounted using ProLong Gold AntiFade with
DAPI and imaged using laser scanning confocal micro-
scope 700 confocal (Zeiss, Jena, Germany).
Histologic ALI scoring
Unlavaged mice lungs were perfused as described above.
The left lung was inflated at 20 cm H2O with 0.25% agarose
in 10% formalin and immersion fixed overnight in 10% for-
malin following current guidelines [20]. The fixed lung was
placed in a molding box, encased in agarose, and 3 mm
thick transverse pieces (apex to base) of the lung were
sliced to ensure adequate sampling of the entire lung for
histological scoring. The lung pieces were paraffin embed-
ded together, sliced at 3 μm thick, and deparafinized and
rehydrated as described above. The slides were stained with
Harris Hematoxylin (2 min), Clarifier 1 (1 min), Bluing re-
agent (1 min), Eosin Y (30 s), dehydrated, and mounted. 4–
5 fields (400X total magnification) of each transversely
sliced lung piece (4–5 pieces total) were scored by a path-
ologist using the scoring system published by American
Thoracic Society [20], which assigns weighted scores for
five parameters of ALI injury and provides a final averaged
score between 0 (no injury) and 1 (most severe).
Cell culture
Primary human alveolar macrophages (hAM) were ob-
tained by bronchoalveolar lavage of de-identified
non-diseased human explanted lungs and enriched by
2 h attachment to tissue culture treated plastic in Ros-
well Park Memorial Institute (RPMI) media with 1%
penicillin/streptomycin. Non-adherent cells were re-
moved by PBS wash. Indicated treatments were per-
formed by incubating in RPMI media with 2% fetal
bovine serum (FBS, HyClone, GE Healthcare, Marlbor-
ough, MA, USA) and 1X penicillin-streptomycin and ei-
ther vehicle (0.1% bovine serum albumin in PBS), 20 ng/
mL tumor necrosis factor α (TNFα, R&D, Minneapolis,
MN, USA), or 50 ng/mL ultrapure E. coli LPS (LPS-EK,
InvivoGen, San Diego, CA, USA) for either 6 h or 24 h.
Peripheral Blood Mononuclear Cell Derived Macro-
phages (PBDM) were enriched by negative selection from
whole blood using DynaBeads Untouched Human Mono-
cyte Kit and by attachment to tissue culture plastic. Treat-
ment with macrophage colony stimulating factor (20 ng/
mL MCSF, R&D) over six days was used to differentiate
PBMC into macrophage-like cells. Macrophage differenti-
ation was performed in RPMI under serum free condi-
tions with supplemental 1X non-essential amino acids,
1 mM sodium pyruvate, 2 mM glutamine, and 1X
penicillin-streptomycin for days 1–3 and with additional
10% FBS for days 4–6. For experiments, cells were incu-
bated in RPMI media with 2% FBS and treated with indi-
cated stimuli for 24 h.
BEAS-2B transformed human lung bronchial epithelial
cells were cultured submerged in Dulbecco’s Modified
Eagle Medium (DMEM), high glucose (4500 mg/L)
media with 10% FBS and 1% penicillin/streptomycin. For
experiments, cells were washed once with PBS and then
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incubated in basal DMEM media with 2% FBS and indi-
cated stimuli for 24 h.
Wi38 primary human fetal lung fibroblasts were cul-
tured using Minimum Essential Media (MEM) media
with 10% FBS and 1% penicillin/streptomycin. Cells were
used between passages 8–12 for experiments, during
which they were incubated with the indicated stimuli in
basal MEM media with 2% FBS.
Human adipose stromal/progenitor cells (ASC) isola-
tion, expansion, and characterization have been previously
described [21–23]. Briefly, ASC were obtained by liposuc-
tion from three human donors (two abdominal and one
flank lipoaspirate) and then digested using collagenase I
(Worthington, Lakewood, NJ, USA) under mechanical agi-
tation for 2 h at 37 °C and centrifuged at 300 g for 8 min to
obtain a pellet containing the stromal vascular fraction.
This fraction was filtered using 250 μm Nitex filters (Sefar
America, Buffalo, NY, USA), and red blood cells were lysed
using ammonium chloride potassium lysis buffer (154 mM
NH4Cl, 10 mM KHCO3, and 0.1 mM ethylenediaminetet-
raacetic acid (EDTA)). Cells were then cultured using
Endothelial Cell Growth Medium (EGM2-MV) media
(Lonza, Allendale, NJ). Cells were used for experiments be-
tween passages 4–6. To stimulate TSG-6 secretion [22],
ASC were washed with PBS to remove residual FBS and
then incubated in basal Endothelial Basal Medium-2
(EBM2) media (Lonza) with 20 ng/mL TNFα (R&D) for
24 h. Demographic information of the ASC donors have
been described previously [24].
Human TSG-6 (hTSG-6) western blot
Conditioned media was centrifuged to remove detached
cells (5 min, 600 g) and then mixed with Laemmli buffer.
Proteins were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) using Stain-Free
Criterion TGX 4–20% gradient gels (Biorad), transferred,
and imaged similarly as HC-HA blots. The blot was probed
using goat-anti-hTSG-6 antibody (AF2104, R&D).
hTSG-6 ELISA
Conditioned media was collected and centrifuged (600 g,
5 min) and human TSG-6 (hTSG-6) was measured as previ-
ously described [22] using a highly sensitive sandwich ELISA
developed using commercially available antibodies [25] and
validated by TSG-6 small interfering RNA (siRNA) in human
MSC [25] and ASC [22]. Briefly, Nunc MaxiSorp 96-well
plates were coated with rat anti-hTSG-6 antibody (A38.1.20;
Santa Cruz) diluted in 0.2 M sodium bicarbonate buffer. De-
tection was performed using biotinylated goat anti-hTSG-6
antibody (BAF2104, R&D), Streptavidin-HRP (R&D), HRP
Substrate (R&D) and quenched using 1 M H2SO4. To deter-
mine the extent of TSG-6 secretion relative to cell number,
viable cell numbers were assessed by trypan blue exclusion
and counted by hemocytometer. Recombinant human
TSG-6 (2104-TS-050, R&D) in the absence and presence of
FBS (2%) was used for standard curve (Additional file 2),
since we found that the presence of FBS lowered the magni-
tude of HRP substrate color development. This phenomenon
may be due to TSG-6 forming TSG-6-HC covalent inter-
mediate in the presence of IαI present in the serum and may
explain why efforts to directly measure TSG-6 in human
serum have been particularly challenging [26].
Time-course of macrophage expression of TSG-6 and genes
implicated in HA breakdown in LPS-challenged mice
Expression of mouse TSG-6 (msTSG-6), also known as
TNFα-induced-protein 6 (TNFAIP6), as well as msH
YAL1–2, msTMEM2, and msCEMIP was identified using
Ensembl gene annotation data in a previously published
data set. The detailed methods, pathway analysis of the
RNA-sequencing (RNA-seq) data, and National Center for
Biotechnology Information (NCBI) deposition have been
described here [27]. Briefly, RNA-seq analysis was per-
formed on bone-marrow-derived, recruited and resident
macrophages isolated from bronchoalveolar lavage of
intratracheal LPS treated mice (C57BL/6, 10–12 week old;
0, 3, 6, 9, and 12 dpi).
HA fragmentation assessment in whole lung
HA fragmentation in lung tissue was assessed using a
protocol generously provided by Cleveland Clinic Program
of Excellence in Glycoscience. Briefly, dedicated (non-la-
vaged) lungs were perfused with 10 mL blood buffered sa-
line and flash frozen. Proteinase K (1 mg/mL) resuspended
in 100 mM ammonium acetate (pH 7.0) with 0.01% sodium
dodecyl sulfate was used to lyse 50 mg of tissue (24 h; 60 °
C). 100% ethanol was added to precipitate glycoaminigly-
cans and samples were washed using 75% ethanol. Samples
were resuspended in 100 mM ammonium acetate, and
100 °C heat was used to inactivate Proteinase K. Overnight
benzonase treatment (MilliporeSigma) was used to degrade
nucleic acids, and 100 °C heat was used to inactivate benzo-
nase. 100 and 75% ethanol was then used to precipitate and
wash the samples before resuspending in 100 mM ammo-
nium acetate. Samples were equally divided and paired,
having a half of the sample left untreated, and half treated
with 0.2 turbidity reducing units (TRU) of Streptomyces hy-
aluronidase (Seikagaku, amsbio, Cambridge, MA). All sam-
ples were lyophilized and resuspended in formamide
(MilliporeSigma) for loading on 1% agarose gel (SeaKem
HGT Agarose, Lonza). Gels were stained overnight in
Stains-All (1.25 mg/200 mL in 30% ethanol), equilibrated in
water, destained using light, and imaged using Cy5 695/55
epi-fluorescence filter on ChemiDoc MP [28]. Select-HA of
predetermined sizes (2500, 1000, 500, and 250 kDa HA)
and Select-HA HiLadder (Hyalose, Oklahoma City, Okla-
homa, USA) were used to size HA fragments. Densitometry
of the distribution of HA staining was performed using
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ImageJ as described before [29]. It has been described pre-
viously that agarose gel electrophoresis method is optimally
suited for resolving high and medium molecular weight
HA (> 200 kDa) and that chromatography and polyacryl-
amide gel electrophoresis can provide better resolution and
quantification of low molecular weight HA [30, 31].
HA staining characterization
Confocal Z-stacks were de-identified for the experimental
group, and HA staining was blindly scored. Briefly, three to
five representative 320 × 320 μm images of the left lung
were taken from each mouse. From each image, HA stain-
ing in the peri-broncho-vascular interstitium was sampled
by taking five 9.4 × 9.4 μm representative subselection snap-
shots. A max intensity Z projection was then prepared
using the Fiji distribution of ImageJ [32] and roughness was
calculated by determining the surface area [33] of the plot-
ted intensity of HA staining using the SurfCharJ plugin
[34]. The roughness was normalized by dividing it by the
average staining intensity of the snapshot. A mean normal-
ized roughness was then determined for each mouse.
Bronchoalveolar lavage fluid (BALF) collection and flow
cytometry
Tracheotomy was used to visualize the trachea and insert an
18-gauge angiocatheter (4075, JELCO-W, Smiths-Medical,
Minneapolis, MN). BALF was obtained by five serial instilla-
tions (1 × 1 mL and 4 × 0.9 mL) of PBS containing 2 mM
EDTA (a return of 4 mL of total BALF was consistently ob-
tained with this protocol). For the total CD45+ count, ali-
quots of the five lavages were combined, blocked with
CD16/CD32 (clone 93, eBioscience, ThermoFisher), stained
with CD45 (30-F11, BD, Franklin Lakes, NJ, USA), and
mixed with 123count eBeads (eBioscience). Cells used for
total cell counts were stained and fixed without any centrifu-
gation to avoid variability introduced by pelleting and aspir-
ating. Using the absolute concentration of the counting
beads added and the ratio of total CD45+ events to total bead
events, the concentration of CD45+ cells was determined
and then multiplied by 4 mL to obtain total CD45+ counts.
For BALF cellular differentials, the five lavages were com-
bined and centrifuged, blocked with CD16/CD32
(eBioscience), and stained with CD45 (30-F11, BD), Ly6G
(1A8, Biolegend), CD64 (X54–5/7.1, BD), CD11c (N418,
eBioscience), F4/80 (BM8, eBioscience), CD11b (M1/70,
eBioscience), Siglec-F (E50–2440, BD), CD4 (RM4–5, Biole-
gend), and CD8a (53–6.7, Biolegend). Flow wash buffer con-
sisting of PBS with 9% FBS and 0.5 mM EDTA was used to
resuspend and wash cells. Flow data, which included mini-
mum of 20,000 (PBS group) and 100,000 (LPS group)
CD45+ leukocyte events for each sample, was collected using
LSR II cytometer (BD) and analyzed using Flowjo (Ashland,
Oregon, USA).
ELISA
Albumin-, receptor for advanced glycation end products
(RAGE)-, and HA ELISAs were performed on the com-
bined supernatant obtained from pelleting the first three
BALF aliquots (total 2.6 mL volume). Manufacturer’s proto-
cols were followed, using mouse albumin ELISA quan-
titation set (Bethyl Labs, Montgomery, TX); RAGE
Duoset ELISA (R&D); HA Duoset ELISA (R&D),
using sample dilutions of 1:3000; 1:6; and 1:4 (ctl
group) or 1:12 (LPS group), respectively. Capture
antibody coating and HRP detection were performed
as described for TSG-6 ELISA.
Statistics
Statistical significance was calculated using ANOVA
and Tukey’s multiple comparison test in Prism
(Graphpad, La Jolla, CA). Data points from individual
mice or independent experiments were plotted unless
otherwise specified. Results were considered signifi-
cant at P < 0.05.
Results
Induction and clearance of HC-modified HA during ALI
To investigate the kinetics of HC-HA formation during re-
spiratory infection-induced ALI, we delivered LPS or
Pseudomonas aeruginosa (PA) to the lungs of adult mice
and then probed for HC-HA in whole lung homogenates.
We first assessed HC-HA formation in lung tissue from
mice exposed to LPS or PBS control, by ex vivo treating the
saline perfused and homogenized lung tissue with hyal-
uronidase, which releases any HC linked to HA, followed
by western blot detection of released HC. We observed ex-
tensive HC-HA formation in LPS-exposed lungs at one-day
post instillation compared to contemporaneous PBS con-
trols in both wild type (Fig. 1a) and TSG-6 heterozygous
mice (Additional file 3: Figure A). However, at 4 days
post-LPS challenge, there was minimal HC-modified HA in
the lungs of wild type (Fig. 1a) or TSG-6 heterozygous mice
(Additional file 3: Figure A). We next assessed HC-HA for-
mation using a clinically relevant model of gram negative
PA-bacteria-induced ALI. The extensive HC-HA formation
noted in lungs 2 days post intratracheal instillation of PA
was followed by minimal HC-modified HA at 4 days post
PA instillation in wild type (Fig. 1a) or TSG-6 heterozygous
mice (Additional file 3: Figure B). To confirm that TSG-6
exclusively mediates HC covalent modification, we mea-
sured HC-HA in TSG-6-KO mice and noted no HC-HA at
one-day post LPS instillation compared to wild type and
heterozygous littermates (Fig. 1c).
Having shown HC-HA formation, we studied if lung
levels of the eponymous TSG-6 inducer TNFα or levels
of TSG-6 mRNA paralleled those of HC-modified HA in
ALI induced by LPS. Both TNFα and TSG-6 were rapidly
induced 1 day post LPS instillation with expression
Ni et al. Respiratory Research  (2018) 19:107 Page 5 of 17
levels returning to baseline by day 4 (Fig. 1d-e). To
determine the localization of HC-HA formation, lung
sections from PA-injured lungs were stained for HA
and HC. HC-modified HA determined by
co-localization of HA and HC staining was absent in
uninjured lungs, but was abundant in the
peri-broncho-vascular interstitium following 1- and
2 days post PA instillation (Fig. 1f ). These results
suggest rapid formation and clearance of HC-HA dur-
ing respiratory infection-induced ALI.
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Fig. 1 HC-HA formation after LPS or PA injury. a-c. Abundance of heavy chain (HC)-linked HA in lung lysates detected by western blot using IαI
antibody (recognizing HC) on lungs before (−) and after (+) hyaluronidase (HAse), which releases HC linked to HA. Each lane represents an
individual mouse lung exposed to intratracheally instilled LPS (20 μg; a) or Pseudomonas aeruginosa (PA, 2*106 CFU; b) or control PBS for the
indicated time, noted as days post instillation (dpi). Lung HC abundance was expressed relative to that of total protein, measured by
densitometry (a-b). c. Exclusive role of TSG-6 in forming HC-HA was confirmed using wild type (WT), heterozygous (HT), and knockout (KO) for
TSG-6. d-e. msTNFα and msTSG-6 expression levels measured by qPCR in whole lung following LPS. Data in a-b and d-e analyzed by ANOVA with
Tukey’s multiple comparisons; **P < 0.01, ***P < 0.001, ****P < .0001. f. Immunofluorescence images of HA and HC localization in formalin-fixed,
paraffin-embedded lung sections from control (0 dpi) and PA-injured (1 and 2 dpi) mice, using antibodies against HA binding protein (red) or
HC2 (green), and staining for nuclei with DAPI (Blue). Staining control provided in the last row, using secondary antibody only. Note HC-HA
co-localization in the peri-broncho (Br)-vascular (V) interstitium (white arrow); scale bar 50 μm.
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TSG-6 production by lung resident cells
To determine which lung cells produce the TSG-6 that is
required for forming HC-HA, we investigated TSG-6 pro-
duction by cultured lung macrophages, bronchoepithelial
cells, and fibroblasts. Cells were stimulated with LPS since
previous work identified it as potent stimulator of TSG-6
RNA induction and secretion by myeloid cells [35, 36]. As
a first step, primary alveolar macrophage (hAM) and per-
ipheral blood mononuclear cell derived macrophage
(hPBDM) were stimulated with vehicle or LPS, then
TSG-6 secretion and functionality was assessed in condi-
tioned media by western blot in the presence of serum
containing IαI (the source of HC) or in the absence of
serum (as a negative control). As anticipated, both hAM
and hPBDM secreted TSG-6 (35 kDa) only after stimula-
tion with LPS (Fig. 2a). Notably, secreted TSG-6 formed
covalent TSG-6-HC intermediates (130 kDa) only in the
presence of serum IαI-containing FBS (Fig. 2a-b). Both
LPS and TNFα, the standard and eponymous inducer
of TSG-6 production, induced TSG-6 secretion in
hAM (Fig. 2b) at levels consistent with the magnitude
of mRNA induction (Fig. 2c).
When we next compared different lung cell types to adi-
pose stromal/progenitor cell, which are known to potently
secrete TSG-6 in response to TNFα, we noticed signifi-
cantly different patterns of TSG-6 secretion in response to
TNFα or LPS (Fig. 2d). While hAM secreted TSG-6 more
robustly in response to LPS than TNFα, adipose stromal/
progenitor cell had a potent response to TNFα, but similar
levels of TSG-6 secretion in response to LPS as the hAM.
In contrast, lung fibroblast and bronchoepithelial cells
only responded to TNFα, and bronchoepithelial cells only
showed comparatively minor levels of TSG-6 secretion in
response to TNFα.
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To validate that AM produce TSG-6 in vivo and to de-
termine the relative difference in TSG-6 induction in
bone-marrow-derived, recruited vs. resident AM, we
evaluated our RNA-seq database of resident and re-
cruited alveolar macrophages isolated from bronchoalve-
olar lavage of LPS treated mice (previously published in
[27]). We noted similar early induction of TSG-6 mRNA
that was highest at day 3 following LPS and noted gener-
ally a more robust induction in recruited- compared to
resident AM (Additional file 4).
Assessment of HA remodeling during ALI
Since HC-modified HA was present during early inflam-
mation, but absent at later time points (i.e. day 4), we
sought to determine whether there was breakdown of high
molecular weight (HMW) HA. Accordingly, the abun-
dance of HA fragments of various molecular weights in
lung tissue were measured in LPS- or PBS exposed mice.
When compared to control conditions, shortly following
LPS injury (days 1 and 2), the abundance of HMW HA
fragments (1000–2500 kDa) decreased, while the
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comparisons, *P < 0.05, **P < 0.01. HMW, high molecular weight; SEM, standard error of the mean; AU, arbitrary unit
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abundance of medium molecular weight HA fragments
(250–500 kDa) increased (Fig. 3a-c). Of note, the increased
appearance of medium molecular weight HA fragments in
whole lungs following LPS exposure was similar in
TSG-6-KO mice compared to littermate heterozygous con-
trol mice (Additional file 5: Figure A), suggesting that these
fragments are generated independently of HC-modified
HA. In parallel with these changes in whole lungs, we mea-
sured the total HA content in bronchoalveolar lavage, using
ELISA (which detects HA fragments of all sizes with a
minimum limit of detection between 6 KDa and 15 kDa
[37]). These data showed increased HA levels at day 1
following LPS which returned towards baseline at days 4
and 6 (Additional file 5: Figure B). Similar to findings in
whole lung, there was no significant difference between
TSG-6-KO and control littermates in HA levels in the
bronchoalveolar lavage (Additional file 5: Figure B).
To further quantify and localize HA remodeling, we
adapted a previously described method [38], to detect HA
immunofluorescence on paraformaldehyde-fixed frozen
lung sections assessed with confocal microscopy. Com-
pared to the lamellar pattern of HA staining seen in the
peri-broncho-vascular regions of PBS-exposed control
mice, mouse lungs exposed to LPS exhibited a more
granular and rough HA staining (Fig. 4a, Additional file 6).
To quantify this change in the pattern of HA staining,
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which is thought to represent HA remodeling driven by
HA fragmentation and synthesis, we constructed intensity
surface plots of HA staining and calculated their surface
roughness (Fig. 4b-c). HA staining from LPS-exposed lung
sections had significantly greater surface roughness than
control sections (Fig. 4c).
These results suggested HC-modification-independent
HA fragmentation during ALI. Since HA synthases and hy-
aluronidases are major determinants of HA turnover, we
measured their transcript abundance in lungs exposed to
LPS. All three HA synthases (HAS1–3) were upregulated in
mouse lungs at 1 day following LPS exposure, returning to
baseline by day 4 (Fig. 5a). In contrast, the expression levels
of key somatic tissue hyaluronidases (HYAL1 and HYAL2)
were persistently downregulated in murine lungs following
LPS injury (for up to 6 days after instillation) (Fig. 5b). Of
the two proteins recently implicated in HA breakdown that
exhibit RNA expression in the lung [39–41], TMEM2
(transmembrane protein 2) expression was also persistently
downregulated; however, KIAA1199/CEMIP (cell migration
inducing and hyaluronan binding protein) [40, 41] was
significantly increased at 1 day following LPS exposure,
returning to baseline by day 4 (Fig. 5c).
Since alveolar macrophages can bind and degrade HA
[42], we additionally analyzed hyaluronidase expression
in alveolar macrophage isolated from bronchoalveolar lav-
age using the RNA-seq database described above (Fig. 5d).
In contrast to the whole lung, we noted a stable expres-
sion of msHYAL1–2 and early induction of msTMEM2
that was highest at day 3 in both resident and recruited al-
veolar macrophages. Compared to msHYAL2 and
msTMEM2, msHYAL1 was expressed minimally and
msCEMIP was not detected (one transcript per million
threshold cut-off). Since HYAL2’s ability to degrade HA
b
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depends on CD44 binding of HA at the cell surface
[43, 44], we assessed CD44 expression and noted that
it was highly expressed and increased during reso-
lution reaching peak expression on day 12 in both re-
cruited and resident macrophages (Fig. 5e).
Function of HC-HA formation during ALI
HC-modified HA is critical for neutrophil sequestration in
liver sinusoids during sepsis induced by systemic LPS expo-
sures [6, 7]. We investigated the role of HC-HA formation
on outcomes of lung injury induced by direct lung
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instillation of LPS in TSG-6 sufficient and TSG-6 deficient
mice. TSG-6-KO mice exhibited similar body weight loss
and recovery following lung instillation of LPS (Fig. 6a). To
assess the impact of TSG-6 on lung inflammation, we mea-
sured leukocyte abundance in the airway and airspaces
using flow cytometry on cells harvested by bronchoalveolar
lavage. (Additional file 7). In response to lung instillation of
LPS,TSG-6-KO mice had similar levels of total CD45+ leu-
kocytes, neutrophils, CD11b+ macrophages, CD4+ T cells,
and CD8+ T cells in the bronchoalveolar lavage as their lit-
termate controls at almost all time points studied (Fig.
6b-f). Compared to wild type or heterozygous mice, CD45+
leukocytes were significantly or tended to be higher in
TSG-6-KO mice only at day 4 following LPS. A similar
trend was observed for neutrophils. To gauge the role of
endogenous TSG-6 on the severity of lung injury in this
model, we measured albumin and RAGE in the bronchoal-
veolar lavage as markers of endothelial and epithelial barrier
integrity, respectively (Fig. 6g-h). Both markers were signifi-
cantly elevated at day 1 following LPS injury, followed by
return to baseline, to similar extent and kinetics in
TSG-6-KO and littermate control mice. To confirm these
findings, lungs at day 4 following LPS were formalin-fixed,
paraffin-embedded, hematoxylin and eosin stained, and
scored for lung injury severity (Fig. 6i, Additional file 8)
using current guidelines [20]. Lung injury scores were not
significantly different between TSG-6-KO and -WT mice.
To extend our findings to gram negative bacterial in-
fection, total neutrophil counts and albumin in broncho-
alveolar lavage were similarly assessed following PA
(Fig.7a-b). Compared to heterozygous littermates, lavage
neutrophils and albumin were also significantly or
tended to be higher in TSG-6-KO mice. Together with
the data obtained using LPS, these results suggest a
modest role for HC-HA formation in the onset, severity,
or resolution of lung inflammation and injury during re-
spiratory infection-induced ALI.
Discussion
This study indicates that lung infections induce rapid
covalent modification of HA, which was dependent on the
evolutionarily conserved ability of TSG-6 to form
HC-modified HA. In this context, alveolar macrophages
may be an important source of secreted TSG-6 in the lung.
Concomitant with HC-HA formation, we noted robust HA
fragmentation which was independent of TSG-6. Both
HC-modified HA and airway HA levels subsided with the
resolution of lung injury. However, the TSG-6-dependent
formation of HC-HA in this model did not have a major
impact on the extent of lung inflammation and injury in
this model.
Unlike other glycosaminoglycans (e.g. heparan sulfate,
dermatan sulfate, chondroitin sulfate, and keratan sulfate),
HA’s dissacharide backbone exhibits the least diversity,
because HA cannot be covalently modified by sulfation,
deacetylation, epimerization, and membrane-bound core
proteins. Instead, the evolutionarily conserved TSG-6 me-
diated modification of HA’s N-acetylglucosamine with
serum IαI’s HC is the only known HA covalent modifica-
tion [5, 45]. Preclinical LPS-induced endotoxic shock
models of sepsis showed that HC-modified HA was re-
quired for neutrophil sequestration in the liver [6, 7] and
was overall protective for animal survival [8, 9], indicating
that endogenous TSG-6 secretion is important for the
control of bacteria-induced inflammation and injury.
TSG-6- and IαI-KO mice not only had worse endotoxic
shock outcomes [8, 9], but they also had markedly in-
creased lung neutrophil infiltration [8, 46], suggesting a
protective role for TSG-6-mediated formation of HC-HA
in the lung in controlling local neutrophil recruitment and
accumulation, and/or a major reduction in the pool of re-
cruitable neutrophils to other organs due to liver seques-
tration and removal of circulating neutrophils [10].
Our data indicate a modest impact of TSG-6 on neutro-
phil levels in the bronchoalveolar lavage following lung in-
stillation of LPS, suggesting that the lung production of
TSG-6 may not be a major determinant of acute inflam-
matory cell accumulation, at least in ALI induced by lung
rather than systemic endotoxin exposure. It is possible
that in this more localized injury model, the levels of sys-
temically absorbed LPS were insufficient to cause major
formation of HC-modified HA in the liver with
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subsequent entrapment of neutrophils. In addition, since
the HA expression in liver sinusoidal vasculature is 500-
and 600-fold higher than in the lung vasculature both at
baseline and during endotoxemia [7], much higher levels
of TSG-6 than those locally produced in ALI may be re-
quired to significantly modulate inflammation, including
neutrophil trafficking across lung tissue barriers. This
notion is further supported by the remarkable
anti-inflammatory effects following treatment with ex-
ogenous recombinant TSG-6 in several conditions, includ-
ing models of ALI [8, 47]. These protective effects of
exogenous TSG-6 have been ascribed to its ability to bind
to and inhibit neutrophilic chemokines [48–50], and may
also be linked to an effect on bone marrow myeloid pro-
genitor cell function [22] and stromal cell differentiation
[51–53].
Our report is the first to use knockout mice to investigate
the specific role of TSG-6 and HC-modified HA during
bacterial lung infection. We found that there are similar
trends toward greater neutrophilic inflammation during
TSG-6 deficiency in both LPS and gram negative bacterial
infection models of localized lung injury (Figs. 6a-b and 7).
Since these trends were observed at time points of inflam-
mation that directly followed (4 dpi, LPS) or coincided with
(2 dpi, PA) peak HC-HA levels, our data suggest that
TSG-6 formation of HC-modified HA has modest effect on
the abundance of inflammatory cells in the lung during
acute infections. Considering the magnitude of the differ-
ences in BAL neutrophils and albumin levels, our results
suggest that TSG-6 has a mild, protective role during acute
lung inflammation. Given the well-established role of neu-
trophils in antibacterial defense [54–56], future studies are
needed to carefully dissect whether induction of TSG-6 and
HC-modified HA in the lung has a protective or deleterious
role in eliminating the gram negative bacterial infection.
Additionally, the role of TSG-6 during gram negative bac-
terial sepsis has not been investigated and remains unclear,
since the published reports on the role of TSG-6 and its co-
valent modification of HA during sepsis have been per-
formed using systemic administration of LPS.
Our investigations expand on previous studies that impli-
cated PBMCs as sources of TSG-6 in response to TNFα or
LPS [35, 36], by showing that terminally differentiated
hAM are more versatile producers of TSG-6 compared to
bronchoepithelial cells or lung fibroblasts. Furthermore,
our comparative studies using adipose stem/progenitor cell
suggested that hAM may be quite potent secretors of
TSG-6 during acute inflammation. Locally produced
TSG-6 may be essential for HC-HA formation in various
lung compartments during bacterial or other types of in-
flammation associated with high TNFα levels, a cytokine
implicated in the pathogenesis of a variety of acute and
chronic lung diseases in humans [57–59]. The local levels
of TSG-6 produced in the lungs were not major
determinants of acute lung inflammation and injury follow-
ing LPS instillation. The only significant impact of TSG-6
deficiency in our study was that of a persistent increase in
total inflammatory cell counts in bronchoalveolar lavage,
with a trend of affecting particularly neutrophils during the
resolution of inflammation. The functional significance of
this effect remains to be determined in chronic or irrevers-
ible models of lung injury. Given the lack of differences in
acute lung injury indices in TSG-6-KO mice, we did not ex-
plore the role of TSG-6 on monocyte and macrophage
function. This area has received recent attention in endo-
toxic shock models of systemic sepsis, where TSG-6 has
been implicated in lung macrophage polarization [8, 60], at-
tributed to its modulatory effects on HA interactions with
its receptor CD44 on monocytes [61–63], or to a marked
inflammatory milieu in TSG-6-KO mice that could also im-
pact macrophage functionality and programming [8].
To our knowledge, this report is the first to characterize
the kinetics of HC-HA formation and HA fragmentation
and remodeling during LPS and PA-induced reversible
lung injury in mice. We noted HC-HA covalent interac-
tions followed by rapid clearance of HC-modified HA dur-
ing lung inflammation, suggesting a high HA turnover
during ALI, which resolves within 4 days after LPS intra-
tracheal instillation. Ability to form HC-HA paralleled the
increase in lung levels of TSG-6 and the availability of
serum IαI (the source for HC) in the lung interstitium, as
measured by correlations with markers of endothelial per-
meability (Additional file 9). The fact that the highest
HC-HA levels coincide with peak alveolar permeability
(BAL albumin and RAGE levels, 1 dpi) supports the hy-
pothesis that vascular leak of serum-derived HC substrate
into tissue is a critical step in the formation of HC-HA in
lung tissue, as we have described before [14]. Since TSG-6
was not required for the control of lung injury and barrier
function, it is possible HC-HA formation is not required
for control of lung injury, but necessary for other pro-
cesses that were not investigated, such as airway epithelial
cell survival and homeostasis [64, 65].
Whereas HC-modified HA was not critical for the out-
comes of ALI measured, future investigations will have to es-
tablish the functional role of HA fragmentation and
remodeling in lung injury and repair. Unlike the accumula-
tion and persistence of HC-modified HA observed in histo-
pathological lesions of various chronic lung diseases,
HC-modified HA in our models of ALI did not accumulate
and was accompanied by markedly increased fragmentation
of high molecular weight HA and/or de novo production of
medium molecular weight HA products. Our study design
could not differentiate between these two processes, nor did
it carefully characterize the production of small molecular
weight HA. The latter, however, were included in the total
HA levels we measured in the bronchoalveolar lavage. These
results suggest a key role of hyaluronidases in clearing HA
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to ensure resolution of acute lung inflammation, since hyal-
uronidase deficiency is associated with failure to clear HA
and development of lung fibrosis [66]. However, the tran-
scription of both HYAL1 and HYAL2, which encode the
principal hyaluronidases in human and mice [67] were de-
creased in ALI lungs. Although the actual hyaluronidase ac-
tivity may diverge from the abundance of its mRNA [68],
our data indicate that reactive oxygen species or other hyal-
uronidases may cause the marked HA fragmentation noted
during ALI. We focused on two proteins that impact HA
turnover whose genes are abundantly expressed in the lung:
TMEM2 and KIAA1199/CEMIP [39–41]. Of these, the ex-
pression of CEMIP, a HA-binding protein that promotes HA
degradation via clathrin-mediated endocytosis [39] in the
whole lung paralleled the kinetics of HA fragmentation in
ALI. In turn, in alveolar macrophages, it was the expression
of CD44 that increased during the resolution phase of ALI,
which may indicate a role in the proper clearance of HA
fragments. Future studies should investigate the relative con-
tribution of enzymatic vs. non-enzymatic (i.e. reactive oxygen
species) regulation of HA turnover in ALI.
Conclusions
Our study indicates that both HC-HA formation and
HA degradation are rapidly and transiently induced in
models of gram-negative bacterial respiratory infec-
tions that cause resolving ALI. The rapid HA turn-
over was associated with increased TSG-6 production,
with induction of HA synthases expression, and with
increased HA degradation-promoting CEMIP expres-
sion. While alveolar macrophages are likely sources of
TSG-6 secretion following lung endotoxin exposure,
the endogenous TSG-6-dependent HC-HA formation
had a modest effect on reducing neutrophilic inflam-
matory cell abundance in the bronchoalveolar lavage
during the resolving phases of ALI. TSG-6 is dispens-
able for the inflammatory response to transient ALI
induced by lung infection, but its major role in form-
ing HC-modified HA suggests that it may play a role
in non-resolving inflammatory lung conditions associ-
ated with abnormal HA turnover.
Additional files
Additional file 1: TSG-6 is conserved for catalyzing HC-modification of
HA. A. Modifying HA with heavy chains (HC) of the serum protein inter
alpha inhibitor (IaI), also known as serum-derived HA-associated protein
(SHAP), is the only covalent modification HA can undergo. B. TNFα-
stimulated gene-6 (TSG-6) is an inflammation-induced secreted protein that
exclusively mediates formation of HC-modified HA. Through two transesteri-
fication reactions, TSG-6 transfers HC from IαI onto itself and then onto HA.
To form the TSG-6-HC intermediate, HC is covalently linked to a conserved
serine residue adjacent to the TSG-6 Link domain that binds HA and
facilitates HC transfer [1–5]. The serum protein IaI consists of a chondroitin
sulfate that is covalently linked to the light chain bikunin and two heavy
chains (HC1 and HC2) that can be removed by TSG-6. C. Alignment of TSG-
6 pro-protein (residues 1–47 depicted, hTSG-6 numbering) containing the
signal peptide (highlighted in gray) and start of the HA-binding Link domain
(highlighted in green). The serine residue (highlighted in yellow) responsible
for removing HC from serum IaI and transferring HC onto HA is evolutionar-
ily conserved across all vertebrates including fish, reptile, and bird: Homo
sapiens (human), Mus musculus (mouse), Equus caballus (horse), Bos taurus
(cattle), Pelodiscus sinensis (chinese softshell turtle), and Danio rerio
(zebrafish). CLUSTAL multiple sequence alignment by MUSCLE 3.8 (MUltiple
Sequence Comparison by Log-Expectation); “*” (asterisk) indicates fully
conserved residue. “:” (colon) indicates residues with strongly similar
properties (>0.5 in Gonnet PAM 250); “.” (period) indicates residues with
weakly similar properties (≤0.5 in Gonnet PAM 250). (DOCX 95 kb)
Additional file 2: Human TSG-6 (hTSG-6) ELISA standard curves. hTSG-6
standard curves were obtained using recombinant hTSG-6 (R&D) in the absence
and presence of FBS. FBS reduced the magnitude of HRP substrate color change.
Of note, TSG-6 readily forms covalent complex with HC (TSG-6-HC intermediate,
Fig. 2a-b) at a conserved serine residue (Additional file 1) in the presence of
serum IαI source (e.g. FBS). Formation of the TSG-6-HC intermediate may
sterically hinder the binding of TSG-6 by the capture and detection antibodies of
TSG-6 sandwich ELISA. OD, optical density. (DOCX 43 kb)
Additional file 3: HC-modification of HA after LPS and PA injury. A. HC-
modified HA following LPS injury at 1 and 4 dpi measured as in Fig. 1a.
B. HC-modified HA following PA injury (2*106 CFU) at 2 and 4 dpi
measured as in Fig. 1b. HT denotes heterozygous TSG-6 control littermate.
(DOCX 110 kb)
Additional file 4: TSG-6 expression in resident and recruited mouse
alveolar macrophages. Resident and recruited mouse alveolar
macrophages (msAM) were isolated from bronchoalveolar lavage of LPS
treated mice (20 μg intratracheal; 0, 3, 6, 9, and 12 dpi). Expression level
of msTSG-6 was assessed by RNA-seq and shown as transcripts per million
(TPM). Mean (n = 3 independently pooled samples per time point, 4–7
mice for each pool) and error bar (SD) plotted. ND, not detected; NA, not
applicable; SD, standard deviation. (DOCX 42 kb)
Additional file 5: Effect of TSG-6 deficiency on lung HA molecular weight
distribution and lavage HA levels following LPS injury. A. HA was extracted
from lung tissue (LPS 1 dpi), separated by agarose gel, and visualized as
described in Fig. 3. HT and KO denote TSG-6 heterozygous and knockout
mice. Select-HA consisting of 2500, 1000, 500, and 250 kDa HA was used to
determine the molecular weight. B. HA levels in bronchoalveolar lavage
were measured by ELISA. n = 5–10 mice per group. (DOCX 87 kb)
Additional file 6: Effect of LPS on HA staining. A. Representative images of
paraformaldehyde-fixed, frozen lung sections immunostained as described for
Fig. 4 shown here in detail. Changes in HA staining can be seen in the peri-
broncho-vascular interstitium (white arrow). B. Representative sections from
independent animals (n= 3 mice per group). Br depicts a bronchial airway
and V pulmonary vessels. Scale bar 50 μm. (DOCX 821 kb)
Additional file 7: Schematic of flow strategy applied to lavaged cells
from PBS and LPS treated mice. Bronchoalveolar lavage from mice at
4 day post LPS instillation is depicted to illustrate all the cell populations
assessed. A. Total leukocytes were identified by excluding debris and
doublets and using CD45+ staining. T cells were identified by CD3+
staining and differentiated by CD4+ and CD8+ staining. Neutrophils were
identified by Ly6G+CD64− staining. Macrophages were identified by
CD64+F4/80+ and classified as recruited (CD11b+CD11clow) or resident
(CD11blowCD11c+SiglecF+). B. Counting beads were identified by high
SSC and low FSC and high fluorescence in FITC and PE. (DOCX 154 kb)
Additional file 8: Histologic scoring of ALI lungs. A. Formalin-fixed, paraffin-
embedded mice lungs (4 day post LPS instillation) were stained with
hematoxylin and eosin and scored at high power fields (400X magnification).
Neutrophils marked with blue arrowhead. B. Representative images of lung
sections from LPS injured TSG-6 KO and WT mice compared to PBS control
taken at lower power fields (100X and 200X). Scale bars: 25 μm (400X), 50 μm
(200X), and 100 μm (100X). (DOCX 984 kb)
Additional file 9: Correlation between HC-HA and markers of alveolar
permeability. Correlation plot of HC-HA abundance, measured in arbitrary units
(AU) versus BAL fluid albumin (A) or RAGE (B) levels in individual mice
exposed to LPS for 1 or 4 days compared to PBS control with simple linear
regression line and coefficient of determination (R-squared). (DOCX 36 kb)
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